Timothy A Yap, from the University of Texas MD Anderson Cancer Center, Houston, TX, US, discusses recent advances and challenges in precision cancer medicine, and how we can improve awareness and understanding of this important subject in the wider community.
1. What have been the most important advances in precision cancer medicine in the last year? (0:08)
2. What are the short- and long-term goals of precision medicine in oncology? (1:55)
3. How can we overcome the challenges of tumour heterogeneity and clonal evolution? (2:36)
4. How do you decide which trial to offer patients using precision medicine technologies? (3:46)
5. How can we improve public awareness and understanding of precision medicine? (4:41)
Speaker disclosures: Timothy A Yap has nothing to disclose in relation to this video interview.
Filmed at the American Association for Cancer Research (AACR) Annual Meeting 2018, Chicago, IL, US, April 14–18, 2018.
Share this Video
Related Videos In Prostate Cancer
Fred Saad, ESMO 2022: Highlights in prostate cancer – Phase 3 trials in the STAMPEDE platform protocol
Prof. Fred Saad (University of Montreal Hospital Centre, Université de Montréal, Quebec, Canada) joins touchONCOLOGY to discuss clinical trial highlights in prostate cancer presented at EMSO 2022. He highlights the results from one of the phase 3 STAMPEDE trials, investigating combination abiraterone and enzalutamide or abiraterone and prednisolone, for metastatic hormone sensitive prostate cancer (mHSPC), […]
Fred Saad, ESMO 2022: Phase 3 PROpel trial of abiraterone and olaparib for patients with prostate cancer – Biomarker analysis and updated results
In the PROpel trial, abiraterone and olaparib significantly prolonged radiographic progression free survival in patients with metastatic castration-resistant prostate cancer. Prof. Fred Saad (University of Montreal Hospital Centre, Université de Montréal, Quebec, Canada) joins touchONCOLOGY to discuss the biomarker analysis from the primary analysis, and updated overall survival and safety data. The abstract entitled ‘Biomarker […]
Axel Merseburger, ASCO 2022: Highlights in prostate cancer clinical trials – Phase 3 SHR3680 trial, ENZAMET trial, MAGNITUDE trial, PROPEL trial, phase 2 lutetium 177 trial, VISION trial
ASCO 2022 showcased many important studies in prostate cancer. Prof. Axel Merseburger (Department of Urology, University of Lubeck, Germany), touchONCOLOGY’s Editor-in-Chief, joins us to share his highlights. In this interview he discusses: the phase 3 trial of SHR3680 versus bicalutamide in combination with androgen deprivation therapy in patients with prostate cancer (0:40); the interim overall […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!